BusinessLatest
Replimune's skin cancer drug rejected by FDA again
Replimune's skin cancer treatment has faced another setback as the FDA has rejected its application. This marks a significant challenge for the company in its efforts to bring the drug to market.
0 upvotes
What happened
Replimune's skin cancer treatment has faced another setback as the FDA has rejected its application.
Why it matters
This marks a significant challenge for the company in its efforts to bring the drug to market.